Dr Gatti Brenda Mirembe, the principal investigator on the study says that HIV negative women at high risk of HIV infection will be enrolled on a monthly pill to evaluate its effectiveness and safety in protecting them from acquiring the virus.
Dr. Carolyne Akello, a researcher at MUJHU shows off the dapivirine vaginal ring. While WHO approved it's use as PrEP it's not yet adoptd in Uganda. Studies that established it's efficacy were done in Uganda.
Researchers at Makerere University - John Hopkins Research
Collaboration (MU-JHU) are embarking on a new study to establish the
effectiveness of using the new HIV drug Islatravir in HIV prevention as a Pre-exposure
Dr Gatti Brenda Mirembe, the principal investigator on the study says that HIV
negative women at high risk of HIV infection will be enrolled on a monthly pill
to evaluate its effectiveness and safety in protecting them from acquiring the
virus. The study will also be carried out in Kenya, Botswana, Eswatini, Malawi,
South Africa and Zimbabwe in Africa and the United States.
Brenda says that the drug will be compared with the already rolled
out oral PrEP drug truvada.
//Cue in: “The design of the…
Cue out: “…Support participants equally.//
Dubbed IMPOWER – 022 study, the researchers aim to enrol a total of 4,500 women
aged 16 to 45 years and 200 of them will be followed up from the Mulago Hill-based
Mirembe says the earliest enroller will be in the trial for three
years and the latest for a year noting that they resolved to include young women
because the prevalence of HIV is much higher in those age groups.
//Cue in: “The trial is going…
Cue out: “…about 200 women”. //
Currently, she says they are engaged in study approval processes
with research regulators to ensure that actual work starts by September.
She is optimistic that once successful, this drug will be a game-changer
in HIV prevention as it gives the public choices especially those that can’t
manage taking the only PrEP option so far approved for use in Uganda which a
daily pill and yet they are at high risk of infection.
//Cue in:” If this product works…
Cue out: “…we have options”//
However, as the new drug is being highly anticipated, already the facility has
done studies on other PrEP options such as the Cabotegravir injection and the
dapivirine vaginal ring that are yet to be rolled out for general use even as
studies found them to be effective in preventing infection.
For the dapivirine ring, for instance, the World Health Organisation (WHO)
recommended its use and issued guidelines for its general roll out in January
but it’s still unavailable in many countries including Uganda.
Estimated to cost 29,000 Shillings, officials in the Ministry of Health say the
monthly ring is still expensive for the country to consider and therefore so
far they have not yet started on the national guidelines even as WHO has given
it a nod.
Uganda also still struggles to enrol all the people at high risk
of infection who need the daily Truvada. It’s estimated that between 67, 000
and 68,000 people are enrolled currently, lower than the year 2020 target that
had been set at 90,000 people.
Also, the country recorded a high 48,000 new HIV infections last year, figure
experts say can be greatly reduced by prevention methods such as PrEP.
Dr Clemensia Nakabiito, one of the earliest researchers of HIV in
women in Uganda says it’s frustrating for researchers to continue bringing up
innovations that can’t be adopted. She says they haven’t heard from the
Ministry about how soon the ring for instance will be adopted and yet study
participants keep frequenting them with questions.
//Cue in:” For us researchers…
Cue out: “…and draft guidelines”. //
Ruth Nahurira a former PrEP trial participant urges the Ministry of Health to speedily
approve methods that are proven effective in the research.
Nahurira who is excited by the news of the IMPOWER study says that
it will offer people more options to choose from.
To her, so far, the ring is the option a woman can easily use
without their partner’s consent since she doesn’t have to hide medicine tins or
being spotted swallowing.
“I was excited by the ring. I asked a lot of questions about it
and doctors told me little of that medicine ends in the bloodstream. The
medicine goes to mainly that place that it’s supposed to protect”, she said
calling upon MOH to embrace all options of prevention if the country is to make
gains in the HIV targets.
Meanwhile, the new drug Islatravir has already been found to be well-tolerated
and efficacious in offering protection against HIV in smaller studies carried
Among people who take it as a treatment for HIV, it's classified
as nucleoside reverse transcriptase translocation inhibitor (NRTTI) and
therefore works to stop virus replication.